Industry Events at #ASBRS22

Moderator: Susan Boolbol, MD
Panelists: Brigid Killelea, MD, FACS, Michael Alvarado, MD, Anne Peled, MD, and Lucy De La Cruz, MD

Not all seeds and tracers are created equal… join us as we take a deep-dive in to the technologies currently available for seed localization and axillary staging, alongside a world-class panel of breast surgical oncologists, with years of collective experience across all available seed localization devices on the market. The great localization debates will tackle everything from seed reliability to MRI visibility, metal instruments, accuracy of measurement, clinical efficacy, and much more.

That’s followed by the world-first, in-person launch of the next generation Sentimag® system and new Magseed® markers - built by Endomag, designed by you. Taking on board feedback from thousands of physicians worldwide, see how the new system has built on the strengths that have made Sentimag® so widely adopted, plus added an abundance of new advanced features.

Then, try out the new system with our product experts in an exclusive hands-on demo session.

Food and drinks provided for all attendees.

Please join our esteemed faculty for an educational symposium on the expanding techniques for nipple sparing mastectomies. This program will go beyond the basics as they review how to reduce complications, address the ptotic breast and discuss nerve grafting. We encourage audience participation, discussion, and questions at the end.

Faculty:

Dr. William Scarlett and Dr. Patricia Clark

Contact Info:

For more information, please contact: Kirsten Gonya, kirsten.m.gonya@medtronic.com, 603‑502‑0533

Program Objectives:

• Learn about the recently released data from the RxPONDER trial and how the Oncotype DX Breast Recurrence Score® test can help inform chemotherapy treatment decisions for node-positive breast cancer patients
• Explore how the Breast Recurrence Score® test and RSClin™ tool can help physicians personalize chemotherapy treatment decisions for node-negative breast cancer patients
• Explore ongoing studies on gene signatures that may help identify candidates for radiation therapy deceleration

Program Description:

Dr. Christy Russell (Vice President, US Medical Affairs) will lead a discussion exploring how the Breast Recurrence Score® test can help inform systemic therapy decisions for early node-negative and node-positive breast cancer patients. She will also explore ongoing studies on gene signatures that may help personalize radiotherapy decisions in early breast cancer.

For more information, please contact Thomas Mallick, tmallick@exactsciences.com, 650‑208‑3268.

Activity Description:

At this interactive hands-on workshop, participants will learn about optimizing analgesia during breast procedures with a focus on ultrasound-guided pectoralis (PECS) blocks, serratus plane blocks, and erector spinae plane (ESP) blocks. Participants will learn the indications, benefits, technical tips and evidence supporting the performance of these analgesic techniques.

Learning Objectives:

• Explain the rationale for optimizing pain control patients undergoing surgery for breast cancer, and the impact of uncontrolled postoperative pain
• Define the goals of multimodal analgesia and the relative value of techniques that employ local anesthetics
• Discuss the benefits of opioid-sparing treatment regimens in the care of patients experiencing post-surgical pain
• Apply best practices pertaining to the administration of local anesthetics during breast cancer surgery by both the surgeon and anesthesiologist

Accreditation Statement:

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and Sterling Ops. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement:

Albert Einstein College of Medicine-Montefiore Medical Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment:

This activity is supported by an educational grant from Pacira Biosciences.

Registration Link:

Complimentary but you must pre-register: www.eeds.com/live/583747

Contact Info:

Kiersten Smith-Gaston, 718‑920‑6674, ksmithgast@montefiore.org

Note: This satellite symposium is supported by Pacira Biosciences through an educational grant provided to Albert Einstein College of Medicine-Montefiore Medical Center. CME credits for this activity will be provided by Albert Einstein College of Medicine-Montefiore Medical Center. It is not part of the official program of the ASBrS*. This activity is free to all registered attendees. (*An independent grant from Albert Einstein College of Medicine was provided to the ASBrS in order to offer this satellite symposium during the 23rd Annual Meeting.)

Abstract:

Grab your coffee and join us early to learn more about the advancements in Ultrasound technology with Shear Wave™ Elastography. In the continuum of breast care, there are many opportunities to collaborate to drive superior patient experiences and outcomes. This course will provide an overview of clinical cases and review next generation technology in Ultrasound.

Learning Objectives:

1. Explain ShearWave elastography (SWE) technique in breast lesion evaluation and review its typical characteristics for benign and malignant lesions
2. Discuss how SWE improves specificity and cancer detection of breast ultrasound
3. Manage through false positive and false negative results
4. Describe the correlation of SWE with prognostic features of breast cancer

Description:

SCOUT® Radar localization exclusively spans the care continuum from time of biopsy placement to Targeted Axillary Dissection to excellent surgical outcomes. Discover the state-of-the art localization and lymphatic mapping techniques practiced by key opinion leaders from the Cleveland Clinic and University of Colorado. Learn about upcoming SCOUT product enhancements and the clinical and economic rationale for placing SCOUT at Time of Biopsy.

Presenters:

Brian Czerniecki, MD, PhD; Colleen Murphy, MD, FACS; Stephanie Valente, DO, FACS

Program Objectives:

Upon completion of this CE activity, participants will be able to:

1. Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer
2. Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing
3. Integrate PARP inhibitors into evidence-based, individualized treatment plans for eligible patients with early and advanced breast cancer considering latest efficacy and safety data in the context of clinical practice or clinical trials
4. Manage treatment-related adverse events in patients receiving PARP inhibitors for breast cancer treatment

Description:

Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection.

This PeerView Live Clinical Consults event for in-person and virtual attendees will provide essential information on the biologic rationale for targeting PARP, the latest data and their practical implications, guidance for optimizing biomarker testing, and strategies for improving multidisciplinary collaboration so that patients with breast cancer can make the most of the recent advances with PARP inhibitor therapy.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc.

Note: This satellite symposium is supported by AstraZeneca and Merck & Co., Inc. through independent educational grants. This activity is provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. CME credits for this activity will be provided by Medical Learning Institute, Inc. It is not part of the official program of the ASBrS*. This activity is free to all registered attendees. (*An independent symposium fee from Medical Learning Institute, Inc. was provided to the ASBrS in order to offer this satellite symposium during the 23rd Annual Meeting.)

Featured Guests:

• Moderator: Dr. Richard Fine, Margaret West Comprehensive Breast Center, Memphis, TN
• Dr. Amelia Tower, Texas Health Breast Specialists, Fort Worth, TX
• Dr. Maryam Elmi, The START Center for Cancer Care, San Antonio, TX

Join us for an educational session on the intraoperative use of Perimeter’s groundbreaking margin visualization technology powered by Optical Coherence Tomography (OCT), bringing clarity to margin status at the point of care.

This presentation will cover:

• Technology behind Perimeter’s S-Series OCT, delivering high-resolution specimen imaging for intraoperative margin visualization
• OCT correlations with pathology
• Workflow for bringing OCT into your OR
• Lumpectomy case reviews, including recognizing suspicious tissues
• Bringing AI* to the operating room and investigational study updates
• Panel discussion and Q&A

*Perimeter is currently conducting a randomized control trial to assess its B-Series OCT imaging platform combined with AI technology on the impact of positive margin rates during breast conservation surgery. Perimeter B-Series OCT with ImgAssist AI is not available for sale in the United States. CAUTION: Investigational Device. Limited by U.S. law to investigational use.

Perimeter’s S-Series OCT is cleared by the FDA and available for sale in the U.S.

Program Objective:

Understand data supporting pre-and post-operative treatment planning using Agendia’s assays MammaPrint® and BluePrint®, for patients with breast cancer. Review the latest data and learn about the real-world impact of MammaPrint and BluePrint.

Description:

Join our faculty, Dr. William Audeh, CMO at Agendia, and Dr. Alfred Colfry, Breast Surgical Oncologist and Medical Director at Breast Center Touro Infirmary, in a case-based discussion on the clinical utility of MammaPrint and BluePrint. We encourage audience participation, discussion, and questions at the end.

Program Objective:

Go beyond wire-free localization into the advanced procedures of TAD and Delayed SLNB. Top experts from around the world review the latest data, the emerging procedures, and share their OR footage of their experiences. Get a glimpse of what’s on the horizon with the next generation Sentimag and dive into the ongoing research.

Agenda:

The Latest Magseed® TAD Data
Mr. Peter Barry, London’s Royal Marsden

Delayed SLNB: The Future of Axillary Staging
Kandace P. McGuire, MD - VCU
Melissa Fana, MD - Northwell Health

Magtrace Efficacy for SLNB Post-NAC
Dr. Stefan Paepke, MD - Technical University of Munich

SentiNOT 2.0 Trial and Recruitment Process
Betsy Bonefas, MD – Baylor College of Medicine

• Food and drinks included

Course Description:

Join our distinguished faculty panel for an interactive, case-based discussion focused on advanced techniques, considerations and enabling technologies for oncoplastic surgery. With an emphasis on both the oncologic and psychosocial outcomes of breast cancer treatment, the keynote speakers will address how to expand indications for optimal techniques that prioritize survivorship.

Looking for feedback on a challenging case? We want to hear from you! Attendees will have the opportunity to submit oncoplastic case questions upon registration for the faculty panel to discuss live.

Faculty:

Anne Peled, MD
Co-Director, Sutter Health CPMC Breast Cancer Center of Excellence
San Francisco, CA

Allison DiPasquale, MD
Director of Breast Oncology, Medical City Dallas
Dallas, TX

Monique Gary, DO, MSc, FACS
Medical Director, Grand View Health/Penn Cancer Network
Sellersville, PA

For more information, contact:

Kimmy Sullivan (kimmy.sullivan@stryker.com)

Program Objective:

Through a review of current clinical evidence and case-based examples, join Dr Chatterjee as he discusses the innovative use of closed incision negative pressure therapy to help minimize post operative complications of oncoplastic breast surgery.

Faculty:

Dr. Abhishek Chatterjee, MD, MBA
Chief of the Division of Plastic Surgery
Division of Surgical Oncology
Tufts Medical Center, Boston, MA

Description:

• Discuss innovative solutions and appropriate patient selection that may minimize complications in oncoplastic breast surgery
• Identify the potential benefits of closed incision wound therapy through case-based discussion

For more information, contact: Fran Kleinsteuber, fkleinsteuber@mmm.com.

Presenter:

Martin Dietrich, MD, PhD, FACP
Medical Oncologist, Florida Cancer Specialists and Research Institute
Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Orlando, FL

Program Description:

This program will include an overview of the role of BRCA genes in the homologous recombination repair (HRR) pathway, updates to guideline recommendations to increase awareness of germline BRCA testing to help inform clinical decisions, and examples of laboratory assays available to help assess germline BRCA mutations.

Objectives:

• Inform the multidisciplinary team about the importance of germline BRCA1/2 testing in breast cancer
• Review the prevalence and guideline recommendations regarding germline BRCA1/2 testing in breast cancer
• Discuss important considerations affecting biomarker testing

For more information, please contact Mahlet Abera at mahlet.abera@astrazeneca.com.

Overview:

During this live satellite symposium, a multidisciplinary panel of experts in the management of early-stage HR+/HER2- breast cancer will engage in a case-based discussion regarding the personalization of adjuvant therapy for these patients, particularly those with high-risk disease. Topics will include clinical and molecular factors for risk assessment, recent clinical data with endocrine regimens integrating CDK4/6 inhibitors, and management of adverse events associated with new agents. This program will highlight current best practices and the integration of emerging data into daily practice to optimize outcomes for patients with early-stage HR+/HER2- breast cancer, using a lively tumor-board format with opportunity for audience questions and interaction.

For help or questions please contact: info@gotoper.com

Faculty:

Susan K. Boolbol, MD, FACS, Nuvance Health
Shawna Willey, MD, FACS, Inova Schar Cancer Institute
Jennifer Gass, MD, FACS, Brown, Women & Infants
Chirag Shah, MD, Cleveland Clinic
Toni Storm, MD, PeaceHealth
Sunny Mitchell, MD, Montefiore Medical Center

Description:

With higher adoption of oncoplastic surgery and a convergence of targeted radiation therapy, enhanced surgeon/radiation oncologist collaboration has become more apparent than ever. Please join us for a compelling breakfast symposium during this year’s ASBrS meeting. The gathering features an outstanding panel to discuss how their clinical experience and evidence is driving change and new standard of care in breast conserving surgery.

For more information, contact: Joe Guido, jguido@viderasurgical.com.

Register: www.videraevent.com